What Happens If a Stem Cell Transplant Fails?

When a stem cell transplant fails, the donated cells either never establish themselves in the recipient’s bone marrow or stop functioning after initially taking hold, leaving the patient without a working blood-cell factory. The consequences are immediate and serious: dangerously low counts of white blood cells, red blood cells, and platelets, which opens the door to life-threatening infections and bleeding. Survival rates after graft failure are sobering, but the situation is not always hopeless. Depending on the patient’s overall health, the type of failure, and available donors, several rescue strategies exist, from second transplants to newer cellular therapies.

Two Types of Graft Failure

Doctors distinguish between two forms. Primary graft failure means the transplanted cells never engraft at all. The patient’s blood counts do not recover within the expected window, and testing shows that donor cells are absent or nearly absent from the bone marrow. Secondary graft failure means the donated cells initially take hold and start producing blood cells, but at some point the graft is lost and counts fall again.¹ One large study found that secondary graft failure had a cumulative incidence of about 4.5% over ten years, with a median onset around three months after transplant.²

The distinction matters because primary graft failure tends to be more dangerous. Patients who never engraft remain profoundly immunocompromised from the conditioning chemotherapy or radiation they received before transplant, and they face an urgent need for rescue. Secondary graft failure at least means the patient had some functional marrow for a period, though the loss of that function is still a crisis.

Why the Body Rejects Donated Cells

The immune system is the main culprit in most graft failures. Even after conditioning therapy suppresses the recipient’s immune system, residual immune cells can recognize the donated cells as foreign and attack them. Natural killer cells target transplanted cells that lack familiar surface markers, and T cells mount a more targeted assault once they recognize mismatched proteins on the donor cells.³ This process mirrors organ transplant rejection, but with a twist: in a stem cell transplant, the “organ” is the donor’s entire blood-forming system, so rejection means losing the ability to produce blood cells altogether.

The degree of mismatch between donor and recipient surface proteins plays an obvious role. Fully matched donors (usually siblings who share the same tissue type) carry a lower rejection risk than partially matched or unrelated donors. That said, a recent analysis of patients who received a specific type of post-transplant immune suppression found that the rate of late graft failure was similar whether the donor was a half-matched family member or a matched unrelated donor, sitting around 6% at two years for both groups.⁴ That finding suggests that modern prophylaxis regimens have narrowed the gap between donor types, at least for late graft failure.

Immune rejection is not the only cause. Infections can damage the bone marrow environment, conditioning therapy can be too weak to clear enough of the recipient’s own marrow to make room for donor cells, or the transplanted cell dose can simply be too low. In autologous transplants, where a patient’s own stem cells are returned after high-dose chemotherapy, graft failure is rarer but still possible, and the cause often remains unclear after infections, drug toxicity, and poor cell quality have been ruled out.

How Doctors Detect Failure

The first sign is usually blood counts that refuse to recover. After transplant, doctors watch daily for neutrophils (a type of white blood cell) to rise above a threshold, typically around 500 cells per microliter. In a successful transplant, that milestone arrives within roughly two to three weeks.⁵ When counts stay flat well past day 28, the team starts investigating.

The key diagnostic tool is chimerism analysis, a test that determines what fraction of the patient’s blood cells come from the donor versus the patient’s own remaining cells. A healthy transplant should show predominantly donor cells. Falling donor chimerism is an early warning sign that the graft is struggling, and it can signal impending failure before counts drop completely.⁶ International transplant societies have worked to standardize the definitions of graft failure so that the diagnosis is consistent across centers, incorporating both count thresholds and chimerism results.⁷

Disease Relapse After Transplant

Graft failure is not the only way a transplant can “fail” in the broader sense. For patients transplanted because of leukemia or another blood cancer, the disease can come back even when the graft itself is functioning perfectly. Relapse happens because the cancer develops ways to dodge the donor immune system. Leukemia cells can downregulate or lose the surface molecules that donor T cells use to identify and kill them, essentially becoming invisible.⁸

One striking mechanism involves leukemia cells losing an entire copy of the chromosome region that carries tissue-type genes. In a study of patients who relapsed after haploidentical transplants, about a third of those examined had leukemia cells that had deleted the chromosome segment carrying the mismatched tissue markers. The donor’s T cells, which had been trained to attack cells bearing those specific markers, could no longer recognize the mutant leukemia cells at all.⁹ This finding was a landmark in understanding why transplant-based immune control of cancer can collapse seemingly overnight.

Rescue Options When a Graft Fails

When graft failure is confirmed, the medical team has several strategies to consider. The choice depends on the patient’s fitness, whether a suitable donor is available, and the nature of the failure.

Second Transplant

A second allogeneic transplant is considered the most definitive rescue for primary graft failure or severe secondary failure. The reasoning is straightforward: if the first attempt did not establish a working graft, a new transplant from a different (or sometimes the same) donor is the most direct path to restoring blood-cell production. Expert opinion supports re-transplantation as the treatment of choice, switching to a different donor when the failure appears to be immune-mediated.

Second transplants are riskier than first ones. A large analysis of over 3,300 second transplants performed between 2011 and 2021 for disease relapse found that overall survival at two years was about 38%, with treatment-related mortality of 22%.¹⁰ A smaller single-center study reported three-year overall survival of about 35% and treatment-related mortality of 20% at 100 days.¹¹ Those numbers are real, and patients relapsing within six months of the first transplant, those with active disease at the time of the second transplant, and those with significant pre-existing health problems fare considerably worse.

Roughly 80% of patients who undergo a second transplant receive cells from a different donor than the first time.¹⁰ However, analysis has not shown a clear survival advantage for switching donors, so the decision is made case by case based on donor availability and the suspected reason for the first failure.

Donor Lymphocyte Infusion

Donor lymphocyte infusion, or DLI, involves giving the patient additional immune cells from the original transplant donor without repeating the full transplant procedure. The idea is to boost the donor immune presence enough to rescue a faltering graft or fight off returning cancer. DLI has shown particular promise in patients with falling donor chimerism (mixed chimerism), where the graft is still partially present but losing ground. In one study, about two-thirds of patients who received DLI for falling chimerism achieved full donor chimerism, with a median time to full conversion of about five months.¹²

For patients whose cancer has relapsed, DLI can sometimes push the disease back into remission. Among patients who received DLI specifically for relapse in that same study, about half achieved remission.¹² In some cases DLI has even achieved molecular-level eradication of leukemia, where no trace of the cancer can be detected by sensitive genetic testing.¹³ DLI is also being explored in the haploidentical transplant setting, where donors are only half-matched, with encouraging early results.¹⁴

The trade-off with DLI is the risk of graft-versus-host disease, where the infused donor cells attack the patient’s own healthy tissues. Doctors typically start with low cell doses and escalate gradually to manage this risk.

CAR-T Cell Therapy

Engineered immune cells, particularly CAR-T cells, have emerged as a newer option for patients whose transplants fail due to disease relapse. These are immune cells that have been genetically modified in the laboratory to recognize and attack specific markers on cancer cells. For B-cell cancers that relapse after transplant, donor-derived CAR-T cells targeting a protein called CD19 have shown benefit with manageable side effects.¹⁵

For acute myeloid leukemia, the landscape is trickier because the cancer cells lack a single clean target like CD19. Still, early work is encouraging. A report described two patients with relapsed AML after transplant who had already failed other CAR-T approaches but achieved complete molecular remission with a modified CAR-T product targeting a different surface protein, with remissions lasting several months.¹⁶

When comparing CAR-T therapy and a second allogeneic transplant head to head after a failed autologous transplant for diffuse large B-cell lymphoma, one analysis found roughly similar one-year progression-free survival (about 56% for CAR-T versus 54% for allogeneic transplant), but CAR-T had markedly lower treatment-related mortality (about 5% versus 20%).¹⁷ That lower toxicity profile makes CAR-T particularly appealing for patients who may not tolerate a full second transplant.

Survival After Graft Failure

The statistics are frank. A single-center analysis of patients who experienced graft failure after allogeneic transplant found five-year overall survival of just 15%. One-year survival was 31%, meaning roughly two-thirds of patients did not survive the first year after graft failure was diagnosed.¹⁸ Having acute leukemia as the underlying diagnosis was the strongest predictor of worse outcomes in that study. A separate analysis of 89 patients reported a somewhat better five-year survival of about 31%, but the authors still described the overall prognosis as poor, noting that treatment-related mortality was nearly half.¹⁹

One important nuance: a small group of patients with secondary graft failure spontaneously recover their own bone marrow function, a phenomenon called autologous reconstitution. In one study, autologous reconstitution occurred in about 12% of secondary graft failure cases and carried an excellent prognosis.² This is rare, but it represents the best-case scenario for graft failure: the patient’s own stem cells rebound and take over blood production. The catch is that if the original transplant was done for a blood cancer, those returning cells may or may not include the cancer, so close monitoring is essential.

Managing the Vulnerable Period

Whether the team is preparing for a second transplant, administering DLI, or pursuing another strategy, the patient remains in a dangerous window of profound immune deficiency. Standard practice involves aggressive infection prevention: broad-spectrum antibiotics during neutropenia, antifungal medications for persistent fever, antivirals to prevent reactivation of herpes and varicella, medications against a particular type of pneumonia, and vigilant screening for cytomegalovirus.²⁰ Transfusions of red blood cells and platelets become a lifeline during this time, keeping counts high enough to prevent catastrophic bleeding or severe anemia.

Hospital stays lengthen considerably when graft failure occurs. A pediatric study found that patients with graft failure had consistently longer inpatient stays and higher costs compared to those whose transplants engrafted normally, a pattern that persisted even as transplant techniques improved over time.²¹ The financial strain compounds an already overwhelming situation for families.

How Doctors Decide What Comes Next

The decision about whether to attempt a second transplant, try DLI, pivot to CAR-T therapy, or shift to comfort-focused care is one of the hardest in transplant medicine. Several factors weigh heavily: how aggressive the underlying disease is, how quickly the relapse or failure occurred after the first transplant, the patient’s organ function and overall fitness, whether a suitable donor is available, and what transplant-related complications the patient already endured.¹⁰ Patients who relapsed early (within six months) after their first transplant face considerably worse odds with a second attempt, which can tip the calculus toward alternative strategies or palliative care.

The transplant datasets are also shaped by selection: patients who receive a second transplant tend to be the ones doctors judged fit enough to tolerate it. That means published survival numbers for second transplants are probably somewhat optimistic compared to what would happen if every patient with graft failure received one. Recognizing this bias honestly is important when counseling patients and families.

When the Focus Shifts to Comfort

Not every patient is a candidate for aggressive rescue. For those whose bodies have been battered by prior treatments, whose cancer has proven multiply resistant, or who simply decide they have had enough, the transition to palliative and hospice care becomes the most compassionate path. Structured programs that integrate palliative care conversations early in the transplant process can help patients and families navigate this transition more smoothly. One case report described how a formalized serious illness conversation program helped a patient with a failed transplant move from a sole focus on lab numbers and disease treatment toward better symptom control, emotional stability, and renewed personal goals.²²

The presence of palliative care does not mean giving up. In many transplant centers, palliative teams work alongside the transplant team from the start, managing pain, nausea, anxiety, and the psychological weight of treatment. If the transplant fails and curative options run out, those same teams can ease the transition to comfort care without an abrupt handoff.

Age and Transplant Failure

Children and younger patients generally fare better after stem cell transplants than older adults, but they are not immune to failure. A study comparing outcomes in children, adolescents, and young adults with acute lymphoblastic leukemia found that older age groups had higher treatment-related mortality, with five-year rates of 19% in adolescents and 17% in young adults compared to 11% in children. Infection was the most common cause of treatment-related death in the older groups, killing roughly a quarter to a third of those who died from non-relapse causes.²³ Relapse rates, interestingly, were similar across all age groups, hovering around 22 to 25% at five years, suggesting that the transplant’s anti-cancer effect does not weaken much with age. What does change is the body’s ability to tolerate the treatment itself.

For pediatric patients specifically, graft failure adds not only medical complexity but also a disproportionate economic burden on families, since hospitalizations stretch longer and recovery is less predictable.²¹ Parents navigating a child’s graft failure face a uniquely agonizing combination of clinical urgency and financial pressure.

Infections and Their Role in Marrow Problems

Infections are not just a consequence of graft failure; they can also contribute to it. Research into the immune cell patterns of patients with bone marrow failure conditions has found that many of the immune sequences involved closely resemble those triggered by common infections, including tuberculosis, cytomegalovirus, influenza, and HIV.²⁴ The relationship is not fully understood. It may be that infections sometimes serve as the initial trigger for an autoimmune attack on the bone marrow, or that the same immune cell types that fight infections happen to cross-react with marrow cells. Either way, the connection complicates the picture for transplant patients, who are already vulnerable to infections and whose marrow is already under immune stress.

Cytomegalovirus deserves special mention. It is extremely common in the general population, usually harmless in healthy people, but a major threat after transplant. Reactivation of latent CMV can directly damage the bone marrow and complicate engraftment, which is why transplant centers screen for it aggressively and treat it preemptively rather than waiting for symptoms.